Published in Medicine (Baltimore) on May 01, 2016
Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma. Oncotarget (2017) 0.75
Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg (2001) 2.79
Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med (1990) 2.73
Adrenocortical carcinoma: clinical and laboratory observations. Cancer (2000) 2.64
Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol (1984) 2.53
Integrated genomic characterization of adrenocortical carcinoma. Nat Genet (2014) 1.81
Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab (2006) 1.67
Surgery is associated with improved survival for adrenocortical cancer, even in metastatic disease. Surgery (2014) 1.56
Adrenocortical carcinoma. Endocr Rev (2013) 1.46
The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer (2010) 1.30
Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab (2013) 1.20
Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol (2013) 1.16
Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab (2015) 1.07
Outcomes of adrenal cortical carcinoma in the United States. Surgery (2006) 1.03
Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J (2008) 1.00
Clinical characteristics for 348 patients with adrenal incidentaloma. Endocrinol Metab (Seoul) (2013) 0.95
Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma. Mod Pathol (2014) 0.94
Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur Urol (2013) 0.92
Adrenal cortical carcinoma--review of current knowledge and treatment practices. Hematol Oncol Clin North Am (2007) 0.90
Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Surgery (2007) 0.88
EJE prize 2014: current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go? Eur J Endocrinol (2014) 0.87
Myxoid variant of adrenocortical carcinoma: a report of two illustrative cases and a brief review of the literature. Pathology (2014) 0.85
Improving Outcomes in Adrenocortical Cancer: An Australian Perspective. Ann Surg Oncol (2014) 0.85
First Case Report of a Sporadic Adrenocortical Carcinoma With Gastric Metastasis and a Synchronous Gastrointestinal Stromal Tumor of the Stomach. Medicine (Baltimore) (2015) 0.83
Adrenocortical carcinoma. Endocrinol Metab Clin North Am (2015) 0.81
Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis. Endocrinol Metab Clin North Am (2015) 0.81
Adrenocortical carcinoma: a single institution experience. Am Surg (2005) 0.80
A twelve-year experience with adrenal cortical carcinoma in a single institution: long-term survival after surgical treatment and transcatheter arterial embolization. Urol Int (2009) 0.79
Cortisol as a possible marker of metastatic adrenocortical carcinoma: a case report with 3-year follow-up. Anticancer Res (2007) 0.78
Diagnosis and management of adrenal cortical carcinoma. Curr Urol Rep (2007) 0.77
Metabolic engineering of Escherichia coli for the production of L-valine based on transcriptome analysis and in silico gene knockout simulation. Proc Natl Acad Sci U S A (2007) 2.43
Thyroid nodules with initially nondiagnostic cytologic results: the role of core-needle biopsy. Radiology (2013) 2.34
Systems metabolic engineering of Escherichia coli for L-threonine production. Mol Syst Biol (2007) 2.18
Metabolic engineering of Escherichia coli for enhanced production of succinic acid, based on genome comparison and in silico gene knockout simulation. Appl Environ Microbiol (2005) 2.13
Clinicopathologic review of 58 patients with biliary papillomatosis. Cancer (2004) 2.05
Diagnostic accuracy of ultrasound and 18-F-FDG PET or PET/CT for patients with suspected recurrent papillary thyroid carcinoma. Ultrasound Med Biol (2010) 2.04
Systems biotechnology for strain improvement. Trends Biotechnol (2005) 1.98
Ultrasonographic screening for detection of thyroid cancer in patients with Graves' disease. Clin Endocrinol (Oxf) (2004) 1.96
Metastasis to the thyroid diagnosed by fine-needle aspiration biopsy. Clin Endocrinol (Oxf) (2005) 1.95
Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: correlation with pathological findings. Clin Endocrinol (Oxf) (2004) 1.87
The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) (2006) 1.77
The outcomes of first reoperation for locoregionally recurrent/persistent papillary thyroid carcinoma in patients who initially underwent total thyroidectomy and remnant ablation. J Clin Endocrinol Metab (2011) 1.74
Constraints-based genome-scale metabolic simulation for systems metabolic engineering. Biotechnol Adv (2009) 1.60
Integrative genome-scale metabolic analysis of Vibrio vulnificus for drug targeting and discovery. Mol Syst Biol (2011) 1.50
Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab (2004) 1.44
Metabolic engineering of Escherichia coli for the production of polylactic acid and its copolymers. Biotechnol Bioeng (2010) 1.36
The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) (2005) 1.35
Systems biology as a foundation for genome-scale synthetic biology. Curr Opin Biotechnol (2006) 1.31
Application of systems biology for bioprocess development. Trends Biotechnol (2008) 1.30
Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring. Bioorg Med Chem (2004) 1.29
18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope (2005) 1.28
Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin Endocrinol (Oxf) (2009) 1.27
Metabolite essentiality elucidates robustness of Escherichia coli metabolism. Proc Natl Acad Sci U S A (2007) 1.26
Completion thyroidectomy in patients with thyroid cancer who initially underwent unilateral operation. Clin Endocrinol (Oxf) (2004) 1.24
Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab (2008) 1.23
In silico identification of gene amplification targets for improvement of lycopene production. Appl Environ Microbiol (2010) 1.18
Systems metabolic engineering for chemicals and materials. Trends Biotechnol (2011) 1.17
Papillary thyroid carcinoma arising from a thyroglossal duct cyst: a single institution experience. Endocr J (2013) 1.16
Obesity is a risk factor for thyroid cancer in a large, ultrasonographically screened population. Eur J Endocrinol (2013) 1.16
18F-fluorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm. J Clin Endocrinol Metab (2007) 1.11
Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res (2002) 1.09
Inhibitory effects of DA-9601 on ethanol-induced gastrohemorrhagic lesions and gastric xanthine oxidase activity in rats. J Ethnopharmacol (2003) 1.07
Genome-scale metabolic model of methylotrophic yeast Pichia pastoris and its use for in silico analysis of heterologous protein production. Biotechnol J (2010) 1.07
Relationship between serum free T4 (FT4) levels and metabolic syndrome (MS) and its components in healthy euthyroid subjects. Clin Endocrinol (Oxf) (2008) 1.05
Metabolic engineering of microorganisms: general strategies and drug production. Drug Discov Today (2008) 1.04
High basal levels of functional toll-like receptor 3 (TLR3) and noncanonical Wnt5a are expressed in papillary thyroid cancer and are coordinately decreased by phenylmethimazole together with cell proliferation and migration. Endocrinology (2007) 1.04
Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer. Oncology (2004) 1.03
Genome-scale metabolic network analysis and drug targeting of multi-drug resistant pathogen Acinetobacter baumannii AYE. Mol Biosyst (2009) 1.02
Low levels of serum vitamin D3 are associated with autoimmune thyroid disease in pre-menopausal women. Thyroid (2014) 1.01
Technical and oncologic safety of robotic thyroid surgery. Ann Surg Oncol (2013) 1.01